Cicadabio.Co., Ltd
- Biotech or pharma, therapeutic R&D
CicadaBio is advancing a portfolio of novel weight loss compounds with highly differentiated profiles. Our lead candidate has demonstrated 30% greater weight reduction than a leading GLP-1 therapy in preclinical studies, while also maintaining excellent glycemic control. Uniquely, treated animals showed increased muscle mass and achieved the highest lean mass-to-body weight ratios across all study groups—highlighting the potential for superior efficacy and long-term metabolic health.
We’re currently seeking a strategic partner or investor to accelerate development of this program, and we’re open to flexible models including licensing, co-development, or equity participation.
Our non-confidential deck is attach in company profile page, and would welcome the opportunity to speak further in person around BIO, where we’ll also be unveiling additional data on weight maintenance and lean mass preservation post-treatment.
)
)
)
)
){kind=logo}
){kind=logo}
)
){kind=logo}
)
){kind=logo}
){kind=logo}